NCT05607563View on ClinicalTrials.gov

A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

PHASE1UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 31, 2023

Conditions
Advanced Tumor
Interventions
DRUG

PM1009 injection

Participants receive PM1009 intravenously, every 2 weeks

Trial Locations (1)

Unknown

RECRUITING

Shanghai Orient Hospital, Shanghai

Sponsors

Lead Sponsor

Biotheus Inc.
All Listed Sponsors
lead

Biotheus Inc.

INDUSTRY

NCT05607563 - A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours | Biotech Hunter | Biotech Hunter